Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients

Summary Background After the 2015 Middle East respiratory syndrome (MERS) outbreak in Korea, prediction of pneumonia development and progression to respiratory failure was emphasized in control of MERS outbreak. Methods MERS-CoV infected patients who were managed in a tertiary care center during the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2016-11, Vol.73 (5), p.468-475
Hauptverfasser: Ko, Jae-Hoon, Park, Ga Eun, Lee, Ji Yeon, Lee, Ji Yong, Cho, Sun Young, Ha, Young Eun, Kang, Cheol-In, Kang, Ji-Man, Kim, Yae-Jean, Huh, Hee Jae, Ki, Chang-Seok, Jeong, Byeong-Ho, Park, Jinkyeong, Chung, Chi Ryang, Chung, Doo Ryeon, Song, Jae-Hoon, Peck, Kyong Ran
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background After the 2015 Middle East respiratory syndrome (MERS) outbreak in Korea, prediction of pneumonia development and progression to respiratory failure was emphasized in control of MERS outbreak. Methods MERS-CoV infected patients who were managed in a tertiary care center during the 2015 Korean MERS outbreak were reviewed. To analyze predictive factors for pneumonia development and progression to respiratory failure, we evaluated clinical variables measured within three days from symptom onset. Results A total of 45 patients were included in the study: 13 patients (28.9%) did not develop pneumonia, 19 developed pneumonia without respiratory failure (42.2%), and 13 progressed to respiratory failures (28.9%). The identified predictive factors for pneumonia development included age ≥45 years, fever ≥37.5 °C, thrombocytopenia, lymphopenia, CRP ≥ 2 mg/dL, and a threshold cycle value of PCR less than 28.5. For respiratory failure, the indicators included male, hypertension, low albumin concentration, thrombocytopenia, lymphopenia, and CRP ≥ 4 mg/dL (all P  
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2016.08.005